1921
Volume 95, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Current estimates put the prevalence of hepatitis B virus (HBV) infection in Kenya at 5–8%. We determined the HBV infection prevalence in the human immunodeficiency virus (HIV)–negative Kenyan adult and adolescent population based on samples collected from a national survey. We analyzed data from HIV-negative participants in the 2007 Kenya AIDS Indicator Survey to estimate the HBV infection prevalence. We defined past or present HBV infection as presence of total hepatitis B core antibody (HBcAb), and chronic HBV infection (CHBI) as presence of both total HBcAb and hepatitis B surface antigen (HBsAg). We calculated crude and adjusted odds of HBV infection by demographic characteristics and risk factors using logistic regression analyses. Of 1,091 participants aged 15–64 years, approximately 31.5% (95% confidence interval [CI] = 28.0–35.3%) had exposure to HBV, corresponding to approximately 6.1 million (CI = 5.4–6.8 million) with past or present HBV infection. The estimated prevalence of CHBI was 2.1% (95% CI = 1.4–3.1%), corresponding to approximately 398,000 (CI = 261,000–602,000) with CHBI. CHBI is a major public health problem in Kenya, affecting approximately 400,000 persons. Knowing the HBV infection prevalence at baseline is important for planning and public health policy decision making and for monitoring the impact of viral hepatitis prevention programs.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0059
2016-08-03
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/2/348.html?itemId=/content/journals/10.4269/ajtmh.16-0059&mimeType=html&fmt=ahah

References

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST, , 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 22122219.[Crossref]
  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ, , 2015. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386: 15461555.[Crossref]
  3. Bwogi J, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M, Opio A, Downing R, Biryahwaho B, Lewis RF, , 2009. Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci 9: 98108.
  4. Hyams KC, Morrill JC, Woody JN, Okoth FA, Tukei PM, Mugambi M, Johnson B, Gray GC, , 1989. Epidemiology of hepatitis B in eastern Kenya. J Med Virol 28: 106109.[Crossref]
  5. Mutuma GZ, Mbuchi MW, Zeyhle E, Fasana R, Okoth FA, Kabanga JM, Julius K, Shiramba TL, Njenga MK, Kaiguri PM, Osidiana V, , 2011. Prevalence of hepatitis B virus (HBV) surface antigen and HBV-associated hepatocellular carcinoma in Kenyans of various ages. Afr J Health Sci 18: 5361.
  6. Pettigrew NM, Bagshawe AF, Cameron HM, Cameron CH, Dorman JM, MacSween RN, , 1976. Hepatitis B surface antigenaemia in Kenyans with chronic liver disease. Trans R Soc Trop Med Hyg 70: 462465.[Crossref]
  7. National AIDS and STI Control Programme (Kenya), CDC Kenya, U.S. Centers for Disease Control and Prevention, Joint United Nations Programme on HIV/AIDS, United States Agency for International Development, U.S. President's Emergency Plan for AIDS Relief, World Health Organization, 2009. Kenya AIDS Indicator Survey, KAIS, 2007: Final Report. Available at: http://stacks.cdc.gov/view/cdc/12122/Share. Accessed June 22, 2015.
  8. The World Bank, 2016. Population Ages 15–64 (% of total). Available at: http://data.worldbank.org/indicator/SP.POP.1564.TO.ZS/countries?page=1. Accessed April 16, 2015.
  9. Yard EE, Daniel JH, Lewis LS, Rybak ME, Paliakov EM, Kim AA, Montgomery JM, Bunnell R, Abudo MU, Akhwale W, Breiman RF, Sharif SK, , 2013. Human aflatoxin exposure in Kenya, 2007: a cross-sectional study. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 30: 13221331.[Crossref]
  10. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, , 2009. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 18: 846853.[Crossref]
  11. Teshale EH, Kamili S, Drobenuic J, Denniston M, Bakamutamaho B, Downing R, , 2015. Hepatitis B virus infection in northern Uganda: impact of pentavalent hepatitis B vaccination. Vaccine 33: 61616163.[Crossref]
  12. Gumbe A, McLellan-Lemal E, Gust DA, Pals SL, Gray KM, Ndivo R, Chen RT, Mills LA, Thomas TK, KICoS Study Team, , 2015. Correlates of prevalent HIV infection among adults and adolescents in the Kisumu incidence cohort study, Kisumu, Kenya. Int J STD AIDS 26: 929940.[Crossref]
  13. Matthews PC, Gerettic AM, Gouldera PJR, Klenermana P, , 2014. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 61: 2033.[Crossref]
  14. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE, , 1985. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151: 599603.[Crossref]
  15. Harania RS, Karuru J, Nelson M, Stebbing J, , 2008. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 22: 12211222.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0059
Loading
/content/journals/10.4269/ajtmh.16-0059
Loading

Data & Media loading...

  • Received : 27 Jan 2016
  • Accepted : 28 Apr 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error